Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: Clinical facts and figures

Turkish Journal of Pediatrics

Volumn 52, Issue 5, 2010, Pages 443-449

  Harmatz, Paul ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Clinical trial; Enzyme replacement therapy; Mucopolysaccharidosis VI; Review; Treatment outcome

Indexed keywords

GALSULFASE; GLYCOSAMINOGLYCAN; PLACEBO;

ANAPHYLAXIS; ANTIBODY PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENDURANCE; ENZYME REPLACEMENT; FUNCTIONAL STATUS; HUMAN; LUNG FUNCTION; MAROTEAUX LAMY SYNDROME; OUTCOME ASSESSMENT; RANGE OF MOTION; REVIEW; SIDE EFFECT; URINE LEVEL; WALKING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; ENZYME REPLACEMENT THERAPY; FEMALE; HUMANS; MALE; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; RECOMBINANT PROTEINS;

EID: 79551614376     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Maroteaux P, Leveque B, Marie J, Lamy M. A new dysostosis with urinary elimination of chondroitin sulfate B. Presse Med 1963; 71: 1849-1852.
2. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005; 28: 1011-1017.
3. Neufeld EF, Muenzer, J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease (8th ed). New York: McGraw-Hill Medical Publishing Division; 2001: 3421-3452.
4. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007; 120: 405-418.
5. Swiedler SJ, Beck M, Bajbouj M, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with ucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A 2005; 134: 144-150.
6. Malatack JJ, Consolini DM, Bayever E. The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatr Neurol 2003; 29: 391-403.
7. Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 1995; 345: 1398-1402.
8. Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144: 574-580.
9. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005; 115: e681-e689.
10. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006; 148: 533-539.
11. Harmatz P, Giugliani R, Schwartz IV, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 2008; 94: 469-475.
12. Harmatz P, Yu ZF, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of longterm pulmonary function in patients tre-ated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 2010; doi:10.1007/sl0545-009-9007-8.
13. Harmatz P, Kramer WG, Hopwood JJ, Simon J, Butensky E, Swiedler SJ. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatr Suppl 2005; 94: 61-68.
14. Wall J C, Bell C, Campbell S, Davis J. The timed get-up-and-go test revisited: measurement of the component tasks. J Rehabil Res Dev 2000; 37: 109-113.
15. Scarpa M, Barone R, Fiumara A, et al. Mucopolysaccharidosis VI: the Italian experience. Eur J Pediatr 2009; 168: 1203-1206.
16. Byers S, Nuttall JD, Crawley AC, Hopwood JJ, Smith K, Fazzalari NL. Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Bone 1997; 21: 425431.
17. Crawley AC, Niedzielski KH, Isaac EL, Davey RC, Byers S, Hopwood JJ. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest 1997; 99: 651-662.
18. Auclair D, Hopwood JJ, Brooks DA, Lemontt JF, Crawley AC. Replacement therapy in mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol Genet Metab 2003; 78: 163-174.
19. McGill J J, Inwood A C, Coman D J, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age - a sibling control study. Clin Genet 2009; doi:10.1111/j.l399-0004.2009.01324.x
20. The first report of the MPS VI (Mucopolysaccharidosis VI, Maroteaux-Lamy syndrome) Clinical Surveillance Program (CSP). Hendriksz C, Valayannopoulos V, Teles E, Miebach E, Harmatz P, Pastores GM, Steiner R. Abstract from the 2009 Congress of the American Society of Human Genetics. Available at: http://www.ashg.org/cgi-bin/2009/ashg09s (accessed January 7, 2010).
21. Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007; 90: 171-180.
22. Pitz S, Ogun O, Arash L, Miebach E, Beck M. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis? Graefes Arch Clin Exp Ophthalmol 2009; 247: 975-980.
23. Auclair D, Hein LK, Hopwood JJ, Byers S. Intraarticular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval. Pediatr Res 2006; 59: 538-543.
24. Auclair D, Hopwood JJ, Lemontt JF, Chen L, Byers S. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI. Mol Genet Metab 2007; 91: 352-361.
25. Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 2007; 91: 61-68.